Related Experiment Video
Updated: May 20, 2025
11:29
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
10.8K
Reduced miR-212-3p is a novel indicator of estimating disease activity in pediatric Crohn's disease
WenXin Chen1, Li Gu2, Xue Qiao1
1Department of Gastroenterology, Children's Hospital of Nanjing Medical University, Nanjing, China.
Journal of Pediatric Gastroenterology and Nutrition
|May 19, 2025
Insights
MicroRNA-212-3p in serum and intestinal tissue shows promise for evaluating pediatric Crohn's disease (CD) activity. This non-coding RNA outperforms traditional markers like fecal calprotectin and CRP in assessing disease severity.
Area of Science:
- Gastroenterology
- Molecular Biology
- Biomarker Discovery
Background:
- Mammalian non-coding RNA databases indicate a strong correlation between miR-212-3p and Crohn's disease (CD).
- Understanding the role of specific microRNAs in pediatric CD is crucial for accurate diagnosis and management.
Purpose of the Study:
- To investigate the differential expression of miR-212-3p in serum and intestinal mucosa of children with CD.
- To analyze the role of miR-212-3p in evaluating CD disease activity in pediatric patients.
Main Methods:
- Studied 118 children, categorizing them into CD, non-CD, and control groups.
- Measured miR-212-3p expression in serum and intestinal mucosa.
- Assessed disease activity using PCDAI, SES-CD, Chiu's score, and occludin expression; compared biomarker efficacy via ROC curves.
Main Results:
- Intestinal miR-212-3p negatively correlated with PCDAI, SES-CD, and Chiu's scores, and positively with occludin expression (p < 0.05).
- Serum miR-212-3p also negatively correlated with PCDAI and SES-CD (p < 0.05).
- ROC analysis revealed both serum and intestinal miR-212-3p were superior to FC, CRP, and other indicators in assessing CD activity.
Conclusions:
- Intestinal mucosal and serum miR-212-3p demonstrate potential as reliable biomarkers for assessing disease activity in pediatric CD.
- These findings suggest miR-212-3p could improve the monitoring and management of pediatric Crohn's disease.
Abstract
No abstract available in PubMed .
More Related Videos
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
106
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
106
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
116
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
116